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Amyloid aggregates of the amyloid- (A) peptide are implicated
in the pathology of Alzheimer’s disease. Anti-A monoclonal
antibodies (mAbs) have been shown to reduce amyloid plaques in
vitro and in animal studies. Consequently, passive immunization is
being considered for treating Alzheimer’s, and anti-A mAbs are
now in phase II trials. We report the isolation of two mAbs (PFA1
and PFA2) that recognize A monomers, protofibrils, and fibrils
and the structures of their antigen binding fragments (Fabs) in
complex with the A(1–8) peptide DAEFRHDS. The immunodom-
inant EFRHD sequence forms salt bridges, hydrogen bonds, and
hydrophobic contacts, including interactions with a striking
WWDDD motif of the antigen binding fragments. We also show
that a similar sequence (AKFRHD) derived from the human protein
GRIP1 is able to cross-react with both PFA1 and PFA2 and, when
cocrystallized with PFA1, binds in an identical conformation to
A(1–8). Because such cross-reactivity has implications for poten-
tial side effects of immunotherapy, our structures provide a tem-
plate for designing derivative mAbs that target A with improved
specificity and higher affinity.
amyloid  crystal structure  EFRH  monoclonal antibody  EFRHD
Normally soluble proteins and peptides can sometimes ag-gregate into insoluble, self-assembled filamentous aggre-
gates, including amyloid and amyloid-like structures. Current
interest in amyloid fibrils and related aggregates arises from their
involvement in diseases such as Alzheimer’s disease (AD), type
2 diabetes, prion diseases, and other protein misfolding disorders
(1). Because aggregates of the amyloid- (A) peptide have been
implicated in the molecular mechanism of AD, reversing or
preventing A aggregation is an important prospective approach
to AD therapy. Antibodies capable of binding monomeric/low
molecular weight forms of A (in the periphery) or aggregated
states of A (in the brain) reduce the amyloid burden in animal
studies (2). Passive immunization with humanized anti-A
monoclonal antibodies (mAbs) (3) is in phase II trials as an
Alzheimer’s therapy (www.elan.com/researchdevelopment/
Alzheimers/). Because the EFRHD motif (A residues 3–7)
appears to be an immunodominant segment of A (4, 5) and
immunization to the EFRH sequence rescues cognitive function
in mouse models of AD (6, 7), it is important to understand the
structural basis of antibody recognition of this sequence.
At least three mechanisms for immunotherapy of AD have
been proposed. Twomechanisms, microglial activation (8, 9) and
catalytic dissolution (10), require that the antibody enter the
central nervous system; the other mechanism, sometimes called
the peripheral sink hypothesis, does not. In the microglial
activation mechanism (8), antibodies bind to amyloid plaques,
triggering microglia via their Fc receptors. As evidence for this
mechanism, A(1–42) immunization elicits synthesis of anti-A
antibodies and causes A-reactive microglial cells to appear
around plaques (8). In catalytic dissolution, antibodies are
hypothesized to act as chaperones, catalyzing the structural
change of the A peptide from the -strand to an alternative
conformation less prone to aggregation (10). Consistent with this
mechanism, the efficacy of a given mAb depends on the A
sequence element it binds; thus, the mAb 6C6, which recognizes
the A N terminus, is three times more effective in disaggre-
gating A fibrils than the mAb 1C2, which binds to the central
residues of A (10). In the peripheral sink hypothesis (3),
antibodies bind to A in the bloodstream, shifting the distribu-
tion of A between the brain and the peripheral circulatory
system and thereby leading to a net eff lux of A from the central
nervous system to plasma, where it is degraded. Thus, DeMattos
et al. (3) observed a 1,000-fold increase in the plasma A levels
in A-overproducing transgenic mice after peripheral adminis-
tration of m266, an mAb directed against the central domain
of A.
All three mechanisms require antibody binding to A in either
monomer or aggregated forms. Because it remains unclear which
of these mechanisms might ultimately make contributions to AD
therapy, the most appropriate antibodies are those equally
capable of recognizing all assembly forms of A peptides.
Although anti-A mAbs have been described [10D5 (11); 3D6
and 16C11 (9); m266 (12); NAB61 (13); and Ab42.2, Ab40.1, and
Ab9 (14)], neither their structural details nor their specificities
for different forms of A have been reported. Thus, the struc-
tural basis of A binding, which lies at the heart of all three
mechanisms, remains unknown.
When immunizing mice to generate antibodies against A,
one may choose from several different states of A: monomers
(11, 12, 14, 15), oligomers (13), protofibrils, or fibrils (14, 16).
Transient, metastable, spherical oligomers, and protofibrils are
observed during the lag phase (an incubation period of up to
several days preceding amyloid fibril growth phase) of sponta-
neous A fibril growth in vitro from high concentrations of A
and, indeed, during amyloid growth by many peptides and
proteins (17). Because the current wisdom is that spherical
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oligomers and/or protofibrils are the most important toxic
species in AD and other amyloid-associated neurodegenerative
diseases (18), the prevailing controversy about whether these
intermediates are on- or off-pathway in amyloid formation (17)
does not impact the validity of targeting these species therapeu-
tically. Because isolated A(1–40) protofibrils can, depending
on conditions, either dissociate (19) or progress to mature fibrils,
their use as immunogens is problematic. Protofibrils can be
stabilized, however, by the small molecule calmidazolium (CLC),
which allows the preparation of stable protofibrils for structural
studies and for use as an antigen. These CLC-stabilized proto-
fibrils (i) exhibit EM images and hydrogen–deuterium exchange
kinetics essentially identical to normal A protofibrils, (ii) share
with protofibrillar assembly intermediates a poor ability to seed
elongation of the monomer, and (iii) develop into amyloid fibrils,
in analogy to normal protofibrils, but at a much slower rate than
the latter (20).
We report here the isolation of two murine IgG2a mAbs,
anti-protofibril antibodies (PFAs) PFA1 and PFA2, from mice
challenged with a CLC-stabilized protofibril form of A(1–40)
and the structures of their antigen binding fragments (Fabs) in
complex with the A(1–8) peptide DAEFRHDS and with the
AKFRHD peptide from the human glutamate receptor inter-
acting protein, GRIP1 (21). The Fab fragments exhibit binding
to A monomers in the 20–40 nM range, and this binding is
significantly impaired or eliminated in A(1–40) mutants in
which a single residue in the 3–7 segment is replaced with
alanine. The full IgGmolecules bind significantly better than Fab
fragments to A fibrils and protofibrils (0.1–0.2 nM), apparently
because of an avidity effect. Our structures reveal that binding
of both mAbs to the EFRHD sequence is mediated by a
combination of salt bridges, hydrogen bonds, and hydrophobic
contacts, including, in both cases, interactions with a striking
WWDDDmotif in the second heavy-chain (H) complementarity
determining region (CDR) (CDR-H2). These structures provide
a molecular basis for A recognition that can be exploited in the
design of derivative mAbs of enhanced affinity and specificity
(22, 23).
Results
Antibody Isolation and Screening. To isolate aggregate-specific
mAbs (16), we injected mice with CLC-stabilized A(1–40)
protofibrils (20) and screened candidate hybridoma clones for
persistent binding to protofibrils in the presence of large excesses
of monomeric A. A number of unique IgG and IgM mAbs, all
capable of binding to A protofibrils, were isolated. Two of the
IgGs, PFA1 and PFA2, are described here. The mAbs were
screened for protofibril affinity in competition assays with
A(1–40) monomers. PFA1 and PFA2 in IgG form both bind
CLC-stabilized A(1–40) protofibrils with EC50 (measured by
ELISA) 0.15 nM. Binding to mature A(1–40) amyloid fibrils is
similar at 0.07 nM and 0.2 nM, respectively.
Surface Plasmon Resonance (SPR) Demonstrates Avidity Effects and
Elucidates the Epitope. SPR analysis for IgG binding to fibrils and
protofibrils yields results comparable with those from ELISA
(Table 1). ELISAs show that both mAbs bind A(1–40) proto-
fibrils equally well (Table 1), with EC50 values of 0.15–0.16 nM.
ELISA indicates that PFA1 binds more tightly to fibrils than does
PFA2 (0.07 vs. 0.2 nM), and SPR confirms this: the Kd values are
0.018 nM and 0.15 nM, respectively.
SPR experiments also revealed that the Fab fragments of
PFA1 and PFA2 are capable of binding A(1–40) monomers,
with affinities of 39  0.1 nM and 25  4 nM, respectively (Fig.
1a and Table 1). This result indicates that avidity (5, 24) plays an
important role in the binding of the bivalent IgGs to multivalent
fibrils. Although the SPR Kd values are 0.018 nM (PFA1) and
0.15 nM (PFA2) for the polydentate binding of IgGs to fibrils,
the corresponding Kd values for Fabs are 60 and 35 nM,
representing decreased binding by 100- to 1,000-fold. These
values closely match the Kd values for Fab binding to monomer:
39.0 nM (PFA1) and 25 nM (PFA2). The significantly enhanced
binding of the IgG forms of PFA1 and PFA2 to A aggregates,
compared with the monovalent interaction with A, may explain
why competition with A monomers was ineffective at elimi-
nating these linear epitope mAbs during the hybridoma screen-
ing process.
The binding epitope was determined by SPR analysis of
previously described (25, 26) single Ala mutants of A(1–40)
(Fig. 1b). Ala mutation at peptide residue (PR) 8 (Fig. 1b) or
higher (data not shown) consistently yields WT levels of binding
in SPR experiments. The Asp-13 Ala mutant peptide shows
little reduction in binding, consistent with the crystal structures
discussed below, in which Asp-1 is disordered. Binding is nearly
Table 1. ELISA EC50 and SPR Kd values
Antibody binding
to A(1–40)
Protofibrils,
IgG ELISA EC50, nM
Fibrils
Monomer,
Fab SPR Kd, nMIgG ELISA EC50, nM IgG SPR Kd, nM Fab SPR Kd, nM
PFA1 0.15  0.12 0.07  0.01 0.018 60  10 39.0  0.1; 21  7 (IgG)
PFA2 0.16  0.09 0.2  0.2 0.150  0.050 35  1 25  4
Fig. 1. SPR reveals A peptide binding to PFA1 via the EFRHD epitope. (a) Kinetic analysis of A(1–40) (WT) monomer at 0, 1.23, 3.70, 11.1, 33.3, 100, and 300
nM, binding to PFA1 Fab immobilized at densities of 2,720 response units (RU) (shown) and 1,280 RU (data not shown). Duplicate binding responses for each
monomer concentration are overlaid with the global fit of a simple 1:1 interaction model (smooth lines), which yielded ka (1.431 0.003) 104 M1 s1, kd
(5.58 0.01) 104 s1, and Kd 39.0 0.1 nM. (b) WT and Ala-substituted mutants of A(1–40) monomers were sequentially flowed over PFA1 IgG captured
on anti-IgG flow cell surfaces (SPR). Significant RU peaks show good peptide binding, whereas the absence of a peak shows no binding. Results from PFA2 were
essentially identical. The D7A mutation limits but does not completely eliminate binding. The numbering scheme is A(1–40)-specific.
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eliminated for Ala mutations at positions 3, 4, 5, and 6. The
Asp-73 Ala mutant peptide exhibits significantly reduced bind-
ing to both mAbs. Thus, the A binding epitope for PFA1 and
PFA2 was shown by SPR to be the linear sequence EFRHD.
Overall Structure of PFA1 and PFA2 Fab apo and Complex Forms. To
explore the structural basis of binding, we solved the x-ray
structures of the two Fab fragments both alone (apo) and bound
to the peptide fragment A(1–8) (‘‘PFA1-pep’’ and ‘‘PFA2-
pep’’); the amino acid sequence of A(1–8) is DAEFRHDS. The
structures were determined by molecular replacement; the high-
est resolution structure is at 1.65 Å. Additionally, we crystallized
PFA1 with a ‘‘mutant’’ A(2–7) peptide AKFRHD, whose
sequence is found in GRIP1 (residues 110–115), to illustrate the
potential for cross reaction (PFA1–E3K). Abbreviated crystal-
lographic data are presented in Table 2. Full crystallographic
data collection and refinement parameters are presented in
supporting information (SI) Table 5.
In our three complex structures, at least six residues of the
peptide can be traced unambiguously from the electron density
maps (Fig. 2a). In all structures, the electron density for the
CDRs is readily traced. The antigen binding site, which lies in a
cleft between the light-chain (L) and H variable domains, is
formed by four of the six CDRs: CDR-L1, CDR-L3, CDR-H2,
and CDR-H3 (sequences are shown in Table 2). The A(1–8)
peptide adopts nearly identical conformations when bound to
the two Fabs (CRMS deviation for residues 2–8 is 0.48 Å) (Fig.
2b), which is not surprising given that PFA1-Fab and PFA2-Fab
have identical L and similar H sequences.
A(1–8) Binding to PFA1 and PFA2 Features the WWDDD Motif. The
structures of the antibody complexes reveal the key interactions
for substrate binding. Small conformational changes in the two
Fabs at the CDRs accompany peptide binding indicative of
induced fit (SI Table 6). In both structures, the main chain of the
CDR-H3 and CDR-L1 loops moves (maximumC displacement
is 1.7 Å) to accommodate the peptide, alleviating steric clashes.
Peptide binding also induces changes in side-chain conforma-
tions, with H His-97, Trp-53, and Asp-100C (Kabat numbering
is used throughout) changing rotamers with peptide binding (SI
Fig. 4).
The A(1–8) peptide binds in a partially extended coil with no
evident  or  structure. Complex formation between the
A(1–8) peptide andmAb buries 494Å2 and 528Å2 of PFA1 and
PFA2, respectively. A striking feature of the CDR regions of
both mAbs is the WWDDD motif in CDR-H2. The WWDDD
motif is found in other mAbs such as AAO18227 (anti-human
Fc), AAB02362 (anti-f lu), AAQ24154 (anti-human CD16),
AAS00782 (anti-DNA), and Fab28 (anti-HIV1-RT); it appears
to be restricted to the IGHV8 subtype (Ig allele nomenclature
from the IMGT database of Ig genes) (27) gene sequences,
making it an important antigen recognitionmotif. Our structures
provide the first example of the WWDDD motif binding to a
positively charged residue and to an adjoining aromatic residue.
In our structures, both Trp (W) residues and two of the three Asp
(D) residues interact with the bound peptide, particularly resi-
dues Phe-4 and Arg-5, making this motif important in epitope
recognition (Fig. 2b, SI Fig. 5, and SI Table 7).
The key residues of As for binding PFA1 and PFA2 consist
of PRs 3EFRHD7 at the A N terminus (shown in Fig. 2b). They
make bulk of the hydrogen bonds, ion-pair, and van der Waals
interactions with the Fabs (SI Table 7). This EFRHD binding
region is entirely consistent with the epitope derived by SPR, as
discussed above. The carboxyl group of PR Glu-3 is within
hydrogen bonding distance of the side-chain of L His-27D in
both PFA1-pep and PFA2-pep. In both complexes, the side-
Table 2. Abbreviated x-ray data measurement and refinement statistics
Measurement PFA1-apo PFA1-pep PFA1-E3K PFA2-apo1 PFA2-pep
Resolution, Å 2.0 1.65 2.1 2.3 2.5
Rsym 0.05 (0.19) 0.055 (0.467) 0.2 (0.223)* 0.072 (0.359) 0.071 (0.473)
I/I 16.3 (4.5) 21.9 (2.4) 9.8 (4.1) 10.8 (2.8) 12.4 (1.5)
Completeness, % 93.1 (85.1) 90.7 (66.3) 87.6 (65.6) 93.0 (92.8) 96.0 (89.8)
Rfac/Rfree 0.177/0.223 0.182/0.225 0.201/0.261 0.211/0.278 0.208/0.277
Bond RMSD, Å 0.011 0.012 0.009 0.010 0.016
Angle RMSD, ° 1.429 1.436 1.169 1.332 1.573
*Rmerge. Data from two crystals of PFA1-E3K were scaled for higher completeness. Thus, we report Rmerge values in place of Rsym for this
structure.
Fig. 2. PFA1 and PFA2 bind to the A(1–8) peptide. (a) Stereoview of a
simulated-annealing omit map contoured at 3 shows the electron density for
the free DAEFRHDS peptide bound to the CDR of PFA1. (b) Stereoview of the
overlay of the peptides and CDRs highlights the similarity in binding. PFA1-
pep is shown in blue, PFA2-pep is in green. Residues are numbered by the
Kabat scheme.
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chain of PR Glu-3 hydrogen bonds to L Ser27E (N and OG
atoms) and makes some long-range (5 Å) ion-pair interactions
with the L His-93 side chain.
The electrostatic environment of the peptide-binding site is
shown in Fig. 3. PR Phe-4 is buried deep within a binding pocket
consisting of H Trp-47, and Trp-52 belonging to the aforemen-
tionedWWDDDmotif (SI Fig. 5) and the L Leu-96 andHHis-50
residues and makes edge-on hydrophobic interactions with these
residues. PR Phe-4 also makes hydrogen bonds via its main-chain
amide N and carbonyl O to the main-chain of L Ser-92 and the
side chain of L His-27D, respectively. PR Arg-5 makes salt
bridges with H Asp-54 and -56 belonging to the WWDDDmotif,
whereas the side chain of PR His-6 hydrogen bonds to the side
chain of H Asp-100C. Furthermore, PR His-6 makes a parallel
-overlap with L Tyr-32. PR Asp-7 N hydrogen bonds to H
His-97 O. PR Asp-7 makes hydrogen bonds to the side chain of
H His-97 and to L Asn-28 ND2. No hydrogen bonds are made
from the Fabs to the terminal residues PR Asp-1 and PR Ser-8.
In fact, PR Asp-1 is not visible in the electron density maps in
either complex. In both complexes, the amide of PRHis-6 makes
an intramolecular hydrogen bond to the carbonyl oxygen of
Phe-4, stabilizing the peptide conformation.
PFA1 and PFA2 Are Highly Homologous. The similarity of mAbs in
binding to A reflects their sequence similarity: Their light
chains are identical, expressing the kappa IGKV1–117 allele
(27). The PFA1 and PFA2 heavy chains strongly resemble the
product of the IGHV8S7 allele (27); they exhibit 92% sequence
identity with one another, with four residue differences at the
CDRs and one adjacent to CDR-H2 (Table 3). None of the
divergent residues are directly involved in short-range (3.5 Å)
interactions to the peptide. However, the CDR-H3 regions of
PFA1 and PFA2 differ from one another at two adjacent
residues (TT vs. NV) that make 3.8–4.8 Å polar interactions with
the bound peptide; such longer-range effects may contribute to
the nearly 2-fold difference in binding affinity between these two
mAbs and the A monomer.
Binding of PFA1 and PFA2 to Related Sequences. Although the
binding constants of these mAbs for A are significant and
within a therapeutically useful range, the shortness of the A
sequence epitope raises possible specificity issues. A BLAST
search revealed that the only protein in the human genome
containing the AEFRHD sequence is its membrane-associated
amyloid precursor protein. Nonetheless, it is possible that human
sequences related to AEFRHD might cross-react with antibod-
ies, such as PFA1 and PFA2, causing side effects during passive
immunotherapy. Indeed, the SPR studies showed that Ala
replacements at residues 3 and 7 of this epitope do not fully
eliminate binding. BLAST and FASTAS3 searches yielded six
extracellular, secreted, or membrane-associated human proteins
featuring sequences matching 5 of the 6 residues of AEFRHD
(SI Table 8). If we limit our search to the EFRH motif, the
dominant binding motif as revealed by our structures and SPR
studies, we obtain additional hits (SI Table 8).
As a preliminary investigation of the specificity of PFA1 and
PFA2 with respect to the human genome, the WT A(2–7)
peptide AEFRHD and mutants derived from proteins listed in
SI Table 8, AKFRHD, AEIRHD, AEFRSD, and REEFRHEA,
were synthesized, and their affinity for the two Fab fragments
was determined by SPR. AEIRHD and AEFRSD showed no
measurable binding to PFA1 and PFA2. However, we found that
PFA1-Fab binds to AKFRHD (a sequence found GRIP1) with
an affinity 28 times lower than that at which it binds to AEFRHD
(Table 4). Similarly, SPR studies show that PFA2-Fab also binds
to the GRIP1-derived peptide AKFRHD with 35-fold lower
affinity than that at which it binds to AEFRHD (Table 4).
Perhaps more significantly, the peptide sequence REEFRHEA,
derived from the human receptor-related neurotrophic tyrosine
kinase (ROR2), actually binds to PFA1 and PFA2 with approx-
imately twice the affinity of the WT A(2–7) peptide AEFRHD
(Table 4). Thus, although the AEFRHD sequence is unique in
the known mouse and human proteomes, it has near-matches
with several other proteins in both species. These in vitro results
Fig. 3. Electrostatics of binding. The electrostatic potential surface of PFA1
with bound peptide. Blue represents positive charge, red indicates negative
charge, and the apolar surface is shown in white. The A(1–8) peptide is drawn
with carbon (yellow), nitrogen (blue), and oxygen (red). Although the Arg 5
residue sits in a pocket of strong negative charge, the Glu 3 residue has no
correspondingly positive region around it. This position is susceptible to
substitution and cross-reaction.
Table 3. Sequence alignment of PFA1 and PFA2 CDRs
Chain CDR1 CDR2 CDR3
PFA1L QSIVHSNGNTY KVS FQGSHVPLTF
PFA2L QSIVHSNGNTY KVS FQGSHVPLTF
Binding 27** 50 89****
PFA1H GFSLSTSGMG IWWDDDR VRRAHTTVLGDWFAY
PFA2H GFSLRTSGMG IWWDDDK VRRAHNVVLGDWFAY
Binding 26 51** 93**
Italicized text indicates mismatches between PFA1 and PFA2. Bold text indicates binding to peptide. Asterisks
indicate hydrogen bonding at 3.5 Å.  indicates a 3.5- to 5-Å distance between polar atoms.
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do not necessarily imply that the full-length protein will interact
with the mAb in vivo; however, they do illustrate the potential for
complications from cross-reactivity.
A significant portion of the A found in the brain is N-
terminally truncated, and the most prevalent of these modified
forms is one lacking residues 1 and 2 and beginning with a
pyroglutamate residue (pyroglutamate-Glu A). This form is
expected to be resistant to exopeptidase digestion and is also
more amyloidogenic than full length peptides, suggesting that
this A breakdown product might play a significant role in
pathology (28). Because E3 is part of the PFA1/PFA2 epitope,
we expected these mAbs to exhibit diminished affinity for
pyroglutamate-Glu forms of A. In fact, we found that the
peptide pGlu-FRHD is bound by the antibodies 50- to 70-fold
less well than the corresponding WT sequence (Table 4). Thus,
although the pathological roles of the pyroglutamate-Glu A
peptide and other truncated forms of A is yet to be worked out,
in the future it may also be necessary to develop antibodies that
effectively bind to these forms.
PFA1 Complexed with the GRIP1 Peptide. The AKFRHD peptide
from GRIP1 (whose binding to PFA1 and PFA2 was discussed
above) was cocrystallized with PFA1.We observed clear peptide
electron density in a PFA1-AKFRHD cocrystal structure. Bind-
ing of the AKFRHD (‘‘E3K’’) peptide to PFA1 is nearly identical
(CRMSD is 0.23 Å) to that of A(1–8), except that it is the tail
of the substituted lysine residue rather than the glutamate
making a hydrogen bond with L Ser-32 (SI Fig. 6). The Glu-to-
Lys substitution also results in replacing the favorable ion-pair
interaction made by the A peptide to His by a less favorable van
der Waals contact formed between two basic residues. Quanti-
tatively, AEFRHD of the A peptide makes 30% more ion-
pair interactions (12 vs. 9) at short range (4 Å) and60%more
(18 vs. 11) at medium range (between 4 and 6Å) thanAKFRHD.
Because they both make 18 hydrogen bonds, these ion-pairing
differences may possibly account for the 30-fold reduction in
binding of the GRIP1 peptide relative to the A peptide.
Discussion
The structures of mAb Fab fragments in complex with an
N-terminal A peptide illustrate the molecular basis for A
recognition by these mAbs. The interface features a striking
WWDDD motif. Residues in the CDR-L1, CDR-L3, CDR-H2,
and CDR-H3 loops take part in binding.
The accumulated experience of many efforts to obtain anti-
bodies to A suggests that the N terminus may be the immu-
nodominant epitope of this peptide. Furthermore, if aggregated
forms of A are to be targeted in therapy, antibodies to the N
terminus will probably be required, given the poor accessibility
of other portions of the sequence in aggregates (29, 30).
In summary, the structures and binding data presented here
provide insights into at least one way in which the immune system
generates antibodies to bind this epitope, and they also provide
the necessary foundation for structure-based design of antibod-
ies with enhanced properties. Structural modifications in the
CDR residues, for example, may lead to derivative antibodies
with improved binding to the WT sequence and its natural
breakdown products (such as the pyroglutamate-Glu A form)
and reduced binding to related sequences, such as Ror2, found
in the human genome that, if left unaddressed, might lead to
significant side reactions in immunotherapy.
Methods
Preparation of disaggregated monomer (31), mature amyloid
fibrils (31), and CLC-stabilized protofibrils (25) was as de-
scribed. Preparation of hybridoma cell lines and antibody se-
quencing is described in SI Text. The mAb purification and
papain fragmentation protocol was adapted from Goding (ref.
32, chap. 9).
IgG affinities for A(1–40) fibrils and protofibrils were mea-
sured by using a microtiter plate assay as described in ref. 16. A
full description of the SPR binding experiments is in SI Text.
Brief ly, binding studies were performed at 20°C by using
BIAcore (Uppsala, Sweden) 2000 optical biosensors equipped
with CM5 sensor chips.
Reagents 37–47 from the Hampton Index (33) were used for
initial screening, and some initial apo hits were obtained by using
the PHOENIX crystallization robot (Art Robbins Instruments,
Sunnyvale, CA). Data were indexed, integrated, and scaled with
the HKL2000 package (34). The original PFA2 triclinic apo
structure was solved by molecular replacement, using the con-
stant (CLCH1) and variable portions of FAB4C6 (PDB ID
code 1NCW) separately (35). Protein rebuilding, including wa-
ter-picking, was performed in Coot (36); refinement was con-
ducted with Refmac5 (37). A partially refined PFA2 apo model
was idealized and used for solution of the other structures.
Structures were validated with SFCHECK (38), PROCHECK
(39), and MOLPROBITY (40).
Abbreviated data collection and refinement statistics appear
in Table 2. Full crystallization conditions, validation informa-
tion, and statistics appear in SI Table 5 and SI Text. Buried
surface area was calculated with Areaimol with a 1.4-Å probe
radius.
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